p53 Mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies

Blood

Volumn 84, Issue 9, 1994, Pages 3148-3157

  Wattel, Eric ^b   Preudhomme, Claude ^b   Hecquet, Bernard ^b   Vanrumbeke, Michael ^b   Quesnel, Bruno ^b   Dervite, Isabelle ^b   Morel, Pierre ^b   Fenaux, Pierre ^a  

^a CHU Rouen BG   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FLUDARABINE; PREDNISONE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; LEUKEMIA REMISSION; MALE; MULTIDRUG RESISTANCE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

EID: 0028172868     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v84.9.3148.bloodjournal8493148     Document Type: Article

References (49)

1. Harris CC, Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329:1318, 1993
2. Levine A, Momand J, Finlay C: The P53 tumour suppressor gene. Nature 351:453, 1991
3. Gaidano G, Ballerini P, Gong J, Inghirami G, Neri A, Newcomb E, Magrath I, Knowles D, Dalla Pavera R: p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88:5413, 1991
4. Ahuja H, Bar-eli M, Arlin Z, Advani S, Allen SL, Goldman J, Snyder D, Foti A, Cline M: The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J Clin Invest 87:2042, 1991
5. Fenaux P, Preudhomme C, Lai JL, Quiquandon I, Jonveaux PH, Vanrumbeke M, Sartiaux C, Morel P, Loucheux-Lefebvre MH, Bauters F, Berger R, Kerckaert JP: Mutations of the P 53 gene in B cell chronic lymphocytic leukemia. A report on 39 cases with cytogenetic analysis. Leukemia 6:246, 1992
6. Fenaux P, Jonveaux P, Quiquandon I, Lai JL, Pignon JM, Loucheux-Lefebvre MH, Bauters F, Berger R, Kerckaert JP: p53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood 78:1652, 1991
7. Jonveaux P, Fenaux P, Pignon JM, Lai JL, Quiquandon I, Kerckaert JP, Loucheux-Lefebvre MH, Goossens M, Bauters F, Berger R: Mutations of the P53 gene in myelodysplastic syndromes. Oncogene 6:2243, 1991
8. Ichikawa A, Hotta T, Takagi N, Tsushita K, Kinoshita T, Nagai H, Murakami Y, Hayashi K, Saito H: Mutations of P53 gene and their relation to disease progression in B-cell lymphoma. Blood 79:2701, 1992
9. Fenaux P, Jonveaux P, Quiquandon I, Preudhomme C, Lai JL, Vanrumbeke M, Loucheux-Lefebvre MH, Bauters F, Berger R, Kerckaert JP: Mutations of the p53 gene in B cell acute lymphoblastic leukemia. A report on 60 cases. Leukemia 6:42, 1992
10. Preudhomme C, Facon T, Zandecki M, Vanrumbeke M, Lai JL, Nataf E, Loucheux-Lefebvre MH, Kerckaert JP, Fenaux P: Rare occurrence of P53 gene mutations in multiple myeloma. Br J Haematol 81:440, 1992
11. Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, Raffeld M: p53 mutation is associated with progression in follicular lymphomas. Blood 82:1994, 1993
12. Caron De Fromentel C, Soussi T: p53 tumor suppressor gene: A mode for investigating human mutagenesis. Genes Chromosom Cancer 4:1, 1992
13. Silvestrini R, Benini E, Daidone MG: p53 as an independant prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 95:965, 1993
14. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J: Small subgroup of aggressive, highly proliferative prostalic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84:883, 1992
15. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F: p53 expression and prognosis in gastric carcinoma. Int J Cancer 50:859, 1992
16. Marchetti A, Buttitta F, Merlo G, Diella F, Pellegrini S, Pepe S, Macchiarini P, Chella A, Angeletti A, Callahan R, Bistacchi M, Squartini F: p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res 53:2846, 1993
17. El Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R, Newcomb EW: p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82:3452, 1993
18. Orita M, Suzuki Y, Sekuja T, Hayashi K: Rapid and sensitive detection of point mutations and DNA polymorphisms using the PCR. Genomics 5:874, 1989
19. Fenaux P, Preudhomme C, Quiquandon I, Jonveaux P, Lai JL, Vanrumbeke M, Loucheux-Lefebvre MH, Bauters F, Berger R, Kerckaert JP: Mutations of the P53 gene in acute myeloid leukemia. Br J Haematol 80:178, 1992
20. Lepelley P, Preudhomme C, Vanrumbeke M, Quesnel B, Cosson A, Fenaux P: Detection of p53 mutations in hematological malignancies: Comparison between immunocytochemistry and DNA analysis. Leukemia (in press)
21. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposed revised criteria for the classification of acule myeloid leukemia. A report of the French-American-British Cooperative Groups. Ann Int Med 103:626, 1985
22. Bennett J, Catovsky D, Daniel MT, Flandrin G, Galton D, Gralnick H, Sultan C: Proposals for the classification of myelodysplastic syndromes. Br J Haematol 51:189, 1982
23. French Cooperative Group on Chronic Lymphocytic Leukemia: A randomized clinical trail of chlorambucil versus CHOP in stage B chronic lymphocytic leukemia. Blood 75:1422, 1990
24. Ellison RR, Holland JF, Weil M: Arabinosyl cytosine: A useful agent in the treatment of acute leukemia in adults. Blood 32:507, 1968
25. Cox DR: Regression models and life-tables (with discussion). J R Stat Soc B 34:487, 1972
26. Lai JL, Zandecki M, Fenaux P, Le Baron F, Bauters F, Cosson A, Deminatti M: Translocations (5;17) and (7;17) in patients with de novo or therapy related myelodysplastic syndromes. Cancer Genet Cytogenet 46:173, 1990
27. Fenaux P, Collyn D'hooghe M, Lai JL, Bauters F, Loucheux MH, Kerckaert JP: Rearrangement and expression of the p 53 gene in myelodysplastic syndrome and acute myeloid leukemia. Nouv Rev Fr Hematol 32:341, 1990
28. Hu G, Zhang W, Deisseroth AB: P53 gene mutations in acute myelogenous leukaemia. Br J Haematol 81:489, 1992
29. Wada M, Bartram CR, Nakamura H, Hachiya M, Chen DL, Borenstein J, Miller CW, Ludwig L, Hansen-hagge TE, Ludwig WD, Reiter A, Mizoguchi H, Koeffler P: Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood 82:3163, 1993
30. 1)-positive acute leukemia. Leukemia 7:1547, 1993
31. Felix CA, Nau MM, Takahashi T: Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia. J Clin Invest 89:640, 1992
32. Ludwig L, Schulz AS, Janssen JWG, Grunewald K, Bartram CR: p53 mutations in myelodysplastic syndromes. Leukemia 6:1302, 1992
33. Thor AD, Moore DH, Edgerton SM, Kawasaki M, Rechsaus E, Lynch E, Marcus J, Schwartz J, Chen L, Maya UB, Smith H: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845, 1992
34. Cheson BD, Jasperse DM, Simon R, Friedman MA: A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 4:1857, 1986
35. Fenaux P, Preudhomme C, Lai JL, Morel P, Beuscart R, Bauters F: Cytogenetics and their prognostic value in de novo ANLL: A report on 283 cases. Br J Haematol 73:61, 1989
36. Schiffer CA, Lee EJ, Tomiyasu T, Wiernik PH, Testa JR: Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 73:263, 1989
37. Fenaux P, Morel P, Rose C, Lai JL, Jouet JP, Bauters F: Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 77:497, 1991
38. Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E, Bauters F, Fenaux P: Cytogenetic analysis has strong independant prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report on 408 cases. Leukemia 7:1315, 1993
39. Hartwell L: Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell1 71:543, 1992
40. Chin KV, Ueda K, Pastan I, Gottesman MM: Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 255:459, 1992
41. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D, Fiere D: Clinical significance of multidrug resistance p-glycoprotein expression in acute nonlymphoblastic leukemia cells at diagnosis. Blood 79:473, 1992
42. Lepelley P, Soenen V, Preudhomme C, Lai JL, Cosson A, Fenaux P: Expression of the multidrug resistance P glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. Leukemia 8:998, 1994
43. Zhao B, Drach D, Hu G, Squires J, Drach J, Deisseroth A, Andreeff M: Absence of regulation of MDR1 by p53 in normal hematopoiesis and acute myelogenous leukemia. Blood 80:202a, 1992 (abstr, suppl)
44. Preudhomme C, Lepelley P, Vachee V, Soenen V, Quesnel B, Cosson A, Fenaux P: Relationship between P53 gene mutations and multidrug resistance (mdr1) gene expression in myelodysplastic syndromes. Leukemia 7:1888, 1993
45. Bhalla K, Ibrado AM, Tourkina E, Tang C, Grant S, Bullock G, Huang Y, Ponnathpur V, Mahoney ME: High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Blood 82:3133, 1993
46. Gunji H, Kharbanda S, Kufe D: Induction of internucleosomal DNA fragmentation in human myeloid leukemia cells by 1-B-D-arabinofuranosylcytosine. Cancer Res 51:741, 1991
47. Lotem J, Sachs L: Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 82:1092, 1993
48. Wada H, Asada M, Nakazawa S, Itoh H, Kobayashi Y, Inoue T, Fukumuro K, Chon Chan L, Sugita K, Hanada R, Akuta N, Kobayashi N, Mizutani S: Clonal expansion of p53 mutant cells in leukemia progression in vitro. Leukemia 8:53, 1994
49. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum M.L, Cavanee W, Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 355:846, 1992